J&J's Janssen nabs new in­di­ca­tion, full ap­proval for can­cer drug Ry­bre­vant

John­son & John­son’s Janssen on Fri­day earned an FDA ap­proval for its can­cer drug Ry­bre­vant (ami­van­tam­ab-vmjw) for the first-line treat­ment of lo­cal­ly ad­vanced or metasta­t­ic non-small cell lung can­cer with epi­der­mal growth fac­tor re­cep­tor (EGFR) ex­on 20 in­ser­tion mu­ta­tions in com­bi­na­tion with oth­er chemother­a­pies.

The ap­proval, which came about a month ahead of time, co­in­cid­ed with the FDA’s con­ver­sion of an­oth­er ac­cel­er­at­ed ap­proval for Ry­bre­vant to a full ap­proval to treat NSCLC with EGFR ex­on 20 in­ser­tion mu­ta­tions in pa­tients whose dis­ease has pro­gressed on or af­ter plat­inum-based chemother­a­py. The ap­provals were based on pos­i­tive re­sults from Janssen’s PA­PIL­LON study, which eval­u­at­ed pro­gres­sion-free sur­vival as a pri­ma­ry out­come and over­all sur­vival as a sec­ondary out­come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER